
Opinion|Videos|July 29, 2024
Limitations of NCCN PD-L1 Expression Recommendations
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How could emergingoverall survival data from trials like
POSEIDON andKEYNOTE-189 impact future treatment guidelines and our understanding of long-term outcomes?
- What evidence supports using dual checkpoint inhibitor therapy plus chemotherapy over chemotherapy alone in the first-line driver-negative setting?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Elinzanetant Shows Consistent Efficacy, Safety, and Sleep Benefits Across Studies
2
Tirzepatide Plus Hormone Therapy Boosts Weight Loss in Menopause: Regina Castaneda, MD
3
Digital, Blood-Based Innovations Transform Alzheimer Disease Detection: Ken Cohen, MD, FACP
4
Revumenib Granted FDA Approval for R/R NPM1-Mutated AML
5














































